financial results
Biocartis Restructures Balance Sheet as H1 2023 Revenues Rise 12 Percent
The company said that its secured creditors have recapitalized its operating subsidiaries and restructured its balance sheet to reduce its debt burden by €132 million.
Centogene Plans Further Cost-Cutting Measures, Seeks Additional Funding Amidst Rising H1 Revenues
For the first half of 2023, Centogene reported a 15 percent year-over-year increase in revenues, driven by both its pharma and diagnostics business segments.
BioMérieux Q2 Revenues Rise 5 Percent
The firm confirmed its 2023 full-year guidance for revenue to increase between 4 percent and 6 percent.
Burning Rock Biotech Q2 Revenues up 12 Percent
The company is continuing to shift its focus to marketing in-hospital test kits with a resulting shrinkage of its central laboratory test volume and revenue.
LumiraDx Q2 Revenues Fall 53 Percent on Lower COVID-19 Demand
The firm also shipped more than 1,500 new instruments, mostly to US pharmacies to prepare for the upcoming respiratory season.
Aug 15, 2023
Aug 9, 2023
Cue Health Q2 Revenues Fall 89 Percent
Aug 9, 2023
QuidelOrtho Revenues up 8 Percent in Q2
Aug 8, 2023
Aug 8, 2023
Quanterix Q2 Revenues Rise 32 Percent
Aug 4, 2023